Riding the Trend or Protecting Profits | Ardelyx, Inc. (ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) went down by -1.20% from its latest closing price compared to the recent 1-year high of $8.81. The company’s stock price has collected 8.23% of gains in the last five trading sessions. Press Release reported 10 hours ago that Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is It Worth Investing in Ardelyx, Inc. (NASDAQ :ARDX) Right Now?

Ardelyx, Inc. (NASDAQ:ARDX) scored a price-to-earnings ratio above its average ratio, recording x from its present earnings ratio. Plus, the 36-month beta value for ARDX is at 1.83. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Ardelyx, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

The average price from analysts is $13.00, which is -$6.17 below the current price. ARDX currently public float of 87.90M and currently shorts hold a 7.21% ratio of that float. Today, the average trading volume of ARDX was 607.49K shares.

ARDX’s Market Performance

ARDX stocks went up by 8.23% for the week, with a monthly jump of 9.85% and a quarterly performance of -5.24%, while its annual performance rate touched 17.61%. The volatility ratio for the week stands at 5.17% while the volatility levels for the past 30 days are set at 4.74% for Ardelyx, Inc.. The simple moving average for the period of the last 20 days is 6.57% for ARDX stocks with a simple moving average of -8.40% for the last 200 days.

Analysts’ Opinion of ARDX

Many brokerage firms have already submitted their reports for ARDX stocks, with Jefferies repeating the rating for ARDX by listing it as a “Buy.” The predicted price for ARDX in the upcoming period, according to Jefferies is $11 based on the research report published on February 18th of the current year 2020.

Citigroup, on the other hand, stated in their research note that they expect to see ARDX reach a price target of $13. The rating they have provided for ARDX stocks is “Buy” according to the report published on February 12th, 2020.

Cowen gave a rating of “Outperform” to ARDX, setting the target price at $13 in the report published on February 10th of the current year.

ARDX Trading at 1.86% from the 50-Day Moving Average

After a stumble in the market that brought ARDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.01% of loss for the given period.

Volatility was left at 4.74%, however, over the last 30 days, the volatility rate increased by 5.17%, as shares surge +0.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.04% lower at present.

During the last 5 trading sessions, ARDX rose by +0.68%, which changed the moving average for the period of 200-days by -15.98% in comparison to the 20-day moving average, which settled at $5.79. In addition, Ardelyx, Inc. saw -16.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ARDX starting from Blanks Robert, who sold 2,049 shares at the price of $5.58 back on Sep 01. After this action, Blanks Robert now owns 115,395 shares of Ardelyx, Inc., valued at $11,425 using the latest closing price.

RAAB MICHAEL, the President & CEO of Ardelyx, Inc., sold 23,128 shares at $7.01 during a trade that took place back on Jul 02, which means that RAAB MICHAEL is holding 24,364 shares at $162,130 based on the most recent closing price.

Stock Fundamentals for ARDX

Current profitability levels for the company are sitting at:

  • -1728.14 for the present operating margin
  • +6.46 for the gross margin

The net margin for Ardelyx, Inc. stands at -1797.77. The total capital return value is set at -44.92, while invested capital returns managed to touch -47.17. Equity return is now at value -65.90, with -43.60 for asset returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Based on Ardelyx, Inc. (ARDX), the company’s capital structure generated 29.30 points at debt to equity in total, while total debt to capital is 22.66. Total debt to assets is 21.06, with long-term debt to equity ratio resting at -15.94. Finally, the long-term debt to capital ratio is 27.27.

When we switch over and look at the enterprise to sales, we see a ratio of 55.12, with the company’s debt to enterprise value settled at 0.19. The receivables turnover for the company is 1.81 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.34.

Related Articles

We Analyzed the Future Direction of KAR Auction Services Inc. (KAR), Here is What We Found

KAR Auction Services Inc. (NYSE:KAR) went up by 1.89% from its latest closing price compared to the recent 1-year high of $26.63. The company’s...

Can Trimble Inc. (TRMB) Remain Competitive?

Trimble Inc. (NASDAQ:TRMB) went up by 1.64% from its latest closing price compared to the recent 1-year high of $54.51. The company’s stock price...

Is There a Dimmer Outlook Ahead for Momenta Pharmaceuticals Inc.?

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) went up by 0.02% from its latest closing price compared to the recent 1-year high of $52.45. The company’s stock...

Latest Posts

We Analyzed the Future Direction of KAR Auction Services Inc. (KAR), Here is What We Found

KAR Auction Services Inc. (NYSE:KAR) went up by 1.89% from its latest closing price compared to the recent 1-year high of $26.63. The company’s...

Can Trimble Inc. (TRMB) Remain Competitive?

Trimble Inc. (NASDAQ:TRMB) went up by 1.64% from its latest closing price compared to the recent 1-year high of $54.51. The company’s stock price...

Is There a Dimmer Outlook Ahead for Momenta Pharmaceuticals Inc.?

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) went up by 0.02% from its latest closing price compared to the recent 1-year high of $52.45. The company’s stock...

Vroom Inc. (VRM): Skating on Thin Ice? We Know the Answer

Vroom Inc. (NASDAQ:VRM) went up by 0.86% from its latest closing price compared to the recent 1-year high of $75.49. The company’s stock price...

Is Geron Corporation (GERN) a Keeper?

Geron Corporation (NASDAQ:GERN) went up by 0.60% from its latest closing price compared to the recent 1-year high of $2.40. The company’s stock price...